| abstract |
Treatment of sexual dysfunction by inhalation of a cGMP PDE 5 inhibitor, especially 5-[2-ethoxy- 5-(4-methylpiperazinylsulfonyl )phenyl] -1-methyl- 3-n-propyl-1, 6-dihydro-7H- pyrazolo[4, 3-d]pyrimidin -7-one, 4-phenylmethylamino -6-chloro-2- (1-imidazolyl) quinazoline, 4-phenylmethylamino -6-chloro-2-( 3-pyridyl) quinazoline, 1,3-dimethyl- 6-(2-propoxy- 5-methanesulfonylamidophenyl) -1,5-dihydropyrazolo[ 3,4-d]pyrimidin -4-one or 1- cyclopentyl-3- ethyl-6-( 3-ethoxy-4- pyridyl) -pyrazolo[ 3,4-d]pyrimidin -4-one. |